Viral respiratory tract infections in young children with cystic fibrosis: a prospective full-year seasonal study
- PMID: 31481063
- PMCID: PMC6724274
- DOI: 10.1186/s12985-019-1208-7
Viral respiratory tract infections in young children with cystic fibrosis: a prospective full-year seasonal study
Abstract
Background: Viral respiratory tract infections are common during early childhood. How they impact cystic fibrosis lung disease history in young children is poorly known. The principal aim of our study was to determinate respiratory tract infections frequency in this cystic fibrosis young population. Secondary outcomes were nature of viral agents recovered and impact of such infections.
Methods: We conducted a prospective cohort study of 25 children affected by cystic fibrosis and aged less than 2 years. Nasal samplings were taken systematically monthly or bimonthly with additional samples taken during respiratory tract infections episodes. Ten pathogens were tested by a combination of five duplex RT-PCRs or PCRs: influenza A and B, respiratory syncytial virus (RSV), metapneumovirus (MPV), rhinovirus/enterovirus (RV/EV)), coronavirus (HKU1, NL63, 229E and OC43), parainfluenza virus (1-4), adenovirus and bocavirus (Respiratory Multi-Well System MWS r-gene®, BioMérieux, Marcy l'Étoile, France). Cycle thresholds (CTs) were reported for all positive samples and considered positive for values below 40. Quantitative variables were compared using a nonparametric statistical test (Wilcoxon signed rank for paired comparisons). Pearson's correlation coefficient (r) was used to assess relationships between two variables. Statistical analyses were performed using SAS v9.4 (SAS Institute, Cary, NC, USA) or GraphPad Prism V6.00 (GraphPad Software, La Jolla, CA, USA). The significance level was set at 0.05.
Results: The mean age at inclusion was 9.6 ± 6.7 months. The patients had 3.4 ± 1.7 respiratory tract infections episodes per child per year. Forty-four respiratory tract infections (69%) were associated with virus: rhinovirus and enterovirus (RV/EV) were implied in 61% of them and respiratory syncytial virus (RSV) in 14%. Only one patient required hospitalization for lower respiratory tract infections. 86% of the patients were treated by antibiotics for a mean of 13.8 ± 6.2 days. RSV infections (n = 6) were usually of mild severity.
Conclusions: Respiratory tract infections in young children with cystic fibrosis were of mild severity, rarely requiring hospitalization. Unsurprisingly, RV/EV were the most frequent agents. RSV-related morbidity seems low in this population. This raises the question of the usefulness of RSV preventive medication in this young population.
Keywords: Children; Cystic fibrosis; Respiratory virus.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Similar articles
-
Incidence and Clinical Course of Respiratory Viral Coinfections in Children Aged 0-59 Months.Adv Exp Med Biol. 2016;905:17-23. doi: 10.1007/5584_2015_185. Adv Exp Med Biol. 2016. PMID: 26801151 Free PMC article.
-
Viral Co-Infections in Pediatric Patients Hospitalized with Lower Tract Acute Respiratory Infections.PLoS One. 2015 Sep 2;10(9):e0136526. doi: 10.1371/journal.pone.0136526. eCollection 2015. PLoS One. 2015. PMID: 26332375 Free PMC article.
-
Coronavirus causes lower respiratory tract infections less frequently than RSV in hospitalized Norwegian children.Pediatr Infect Dis J. 2011 Apr;30(4):279-83. doi: 10.1097/INF.0b013e3181fcb159. Pediatr Infect Dis J. 2011. PMID: 21057374
-
The role of infections and coinfections with newly identified and emerging respiratory viruses in children.Virol J. 2012 Oct 27;9:247. doi: 10.1186/1743-422X-9-247. Virol J. 2012. PMID: 23102237 Free PMC article. Review.
-
Viral-Bacterial Co-infections in the Cystic Fibrosis Respiratory Tract.Front Immunol. 2018 Dec 20;9:3067. doi: 10.3389/fimmu.2018.03067. eCollection 2018. Front Immunol. 2018. PMID: 30619379 Free PMC article. Review.
Cited by
-
Coxsackievirus B infections are common in Cystic Fibrosis and experimental evidence supports protection by vaccination.iScience. 2022 Sep 5;25(10):105070. doi: 10.1016/j.isci.2022.105070. eCollection 2022 Oct 21. iScience. 2022. PMID: 36157581 Free PMC article.
-
Development of Primer Panels for Whole-Genome Amplification and Sequencing of Human Seasonal Coronaviruses: hCoV-OC43, hCoV-HKU1, hCoV-229E, and hCoV-NL63.Viruses. 2024 Dec 25;17(1):13. doi: 10.3390/v17010013. Viruses. 2024. PMID: 39861802 Free PMC article.
-
Cystic Fibrosis: Fighting Together Against Coronavirus Infection.Front Med (Lausanne). 2020 Jun 9;7:307. doi: 10.3389/fmed.2020.00307. eCollection 2020. Front Med (Lausanne). 2020. PMID: 32582746 Free PMC article. No abstract available.
-
Incidence, prevalence, clinical features, and outcomes of COVID-19 in persons with cystic fibrosis: a systematic review protocol.JBI Evid Synth. 2022 Nov 1;20(11):2721-2726. doi: 10.11124/JBIES-22-00018. JBI Evid Synth. 2022. PMID: 35975314 Free PMC article.
-
Research advances in molecular mechanisms underlying the pathogenesis of cystic fibrosis: From technical improvement to clinical applications (Review).Mol Med Rep. 2020 Dec;22(6):4992-5002. doi: 10.3892/mmr.2020.11607. Epub 2020 Oct 16. Mol Med Rep. 2020. PMID: 33173976 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials